3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Phase 3
1
Status
Completed
3
Active not recruiting
3
Not yet recruiting
2
Recruiting
1
Sponsor Class
OTHER
2
INDUSTRY
1
Study Type
Interventional
2
Observational
1
Sponsor
Cancer Type
Breast
3
Gastrointestinal
2
Thoracic
1
Genitourinary
1
Conditions
Breast Neoplasms
667
Neoplasms
588
Colorectal Neoplasms
291
Carcinoma, Non-Small-Cell Lung
289
Prostatic Neoplasms
278
Lung Neoplasms
218
Melanoma
160
Multiple Myeloma
149
Neoplasm Metastasis
145
Head and Neck Neoplasms
143
Pancreatic Neoplasms
140
Ovarian Neoplasms
129
Carcinoma, Hepatocellular
126
Leukemia, Myeloid, Acute
121
Brain Neoplasms
112
Squamous Cell Carcinoma of Head and Neck
109
Colonic Neoplasms
109
Uterine Cervical Neoplasms
107
Stomach Neoplasms
102
Recurrence
101
Lymphoma
100
Glioblastoma
91
Lymphoma, Non-Hodgkin
82
Hematologic Neoplasms
79
Precursor Cell Lymphoblastic Leukemia-Lymphoma
78
Lymphoma, Follicular
77
Urinary Bladder Neoplasms
76
Parkinson Disease 4, Autosomal Dominant Lewy Body
74
Glioma
73
Carcinoma, Renal Cell
71
Interventions
pertuzumab
1
Trastuzumab
1
Surgical Procedures, Operative
1
Radiotherapy
1
Injections, Subcutaneous
1
Ado-Trastuzumab Emtansine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
3 trials
Recent
Start date
Enrollment
Completed
×
Patient Preference
×
1 year
×
Clear all
NCT05415215
2026-02-10
ProHer
Hoffmann-La Roche
Phase 3
Completed
346 enrolled
20 charts
NCT05970471
2025-12-12
IMPLICATION
Centre Hospitalier Universitaire de Besancon
Completed
167 enrolled
NCT05573022
2025-11-17
IMPACTT
Vejle Hospital
Phase NA
Completed
274 enrolled